Fast-track status is intended to speed the development and review of treatments for serious conditions with unmet medical needs. It will allow Spinogenix to have more frequent interactions with the ...

Acurastem has received $7.5 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance AS-241, its lead clinical candidate for amyotrophic lateral sclerosis (ALS) and ...

In this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water ...

Tazbentetol is an investigational, once-daily synaptic regenerative therapy designed to restore cognitive and motor function in ALS.

Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering novel therapeutics that have the potential to restore synapses to improve the lives of patients worldwide, today announced that ...

The drug is for a small subset of patients. But evidence that breathing and strength can get better for some of them is ...

Instead of scheduling many different appointments with different providers, patients like Welling can see all of their ...

The ALS Association today announced the newest recipients of the Hoffman ALS Clinic Development and Capacity Awards, grant ...

Tanea Brooks reveals ALS diagnosis, raising awareness about early symptoms, progression, and the importance of timely detection and supportive care options. , Health, Times Now ...

Ozempic tablets are now available; investigational ALS treatment gains FDA Fast Track status; positive results for aficamten ...

Misshapen proteins cause a mess of trouble—particularly in neurodegenerative diseases. But a new study suggests it's possible ...